Results 61 to 70 of about 3,323,629 (269)

Intermittent androgen deprivation as therapy for androgen-sensitive prostate cancer. Sense or nonsense?

open access: yes, 2012
Androgen deprivation is the predominant therapy for advanced prostate cancer. There is accumulating evidence that phases of intermission in androgen deprivation may have benefits regarding side effects, albeit there is as yet no general recommendation ...
Loertzer, Hagen   +3 more
core   +1 more source

Hyperostosis frontalis interna: Observed patterns, prevalence, and dementia associations in older adults

open access: yesThe Anatomical Record, EarlyView.
Abstract Hyperostosis frontalis interna (HFI) is a frequently underrecognized condition characterized by overgrowth of the frontal endocranium, most commonly observed in post‐menopausal women. Although its etiology remains unclear, hormonal influences and a possible relationship with neurocognitive changes have been proposed.
Danielle Felsberg   +5 more
wiley   +1 more source

Association of different types of androgen deprivation therapy with bone health.

open access: yes, 2017
Association of different types of androgen deprivation therapy with bone health.
Kwan Lun Ho (3716626)   +13 more
core   +1 more source

Localized Prostate Cancer Therapy: Tumor Microenvironment‐Activated Spermine Hydrogel With Real‐Time Autonomous Fluorescence Sensing

open access: yesChemistry – A European Journal, EarlyView.
First tumor microenvironment (TME)‐responsive spermine‐loaded hydrogel with autonomous sensing for advanced local therapy of prostate cancer (PCa) is developed. Spermine can be released from the hydrogel to kill the prostate cancer cells specifically under acidic TME.
Ho‐Fai Chau   +12 more
wiley   +1 more source

Comparing the safety and efficacy of systemic therapies for high-risk biochemically recurrent hormone-sensitive prostate cancer: a network meta-analysis

open access: yesFrontiers in Oncology
IntroductionEnzalutamide is the only androgen receptor pathway inhibitor approved by the United States Food and Drug Administration and the European Medicines Agency to treat high-risk biochemically recurrent non-metastatic hormone-sensitive prostate ...
Armen Aprikian   +10 more
doaj   +1 more source

A randomized controlled trial on the effectiveness of strength training on clinical and muscle cellular outcomes in patients with prostate cancer during androgen deprivation therapy: rationale and design

open access: yesBMC Cancer, 2012
Background Studies indicate that strength training has beneficial effects on clinical health outcomes in prostate cancer patients during androgen deprivation therapy.
Thorsen Lene   +5 more
doaj   +1 more source

Successive xanthogranulomatous prostatitis after complete remission of metastatic prostate adenocarcinoma: An extremely rare case report with review of literatures

open access: yesUrology Case Reports, 2020
Xanthogranulomatous prostatitis is a rare occasion that mimics the prostate cancer in every aspect of clinical diagnosis. These two occasions require totally diverse therapeutics principles. Thus, emphasis should be exerted to distinguish them.
Che-Hsueh Yang   +5 more
doaj   +1 more source

Effects of androgen deprivation therapy on telomere length [PDF]

open access: yesClinical Endocrinology, 2017
Summary Objective Recent evidence suggests that androgens either directly or via aromatisation to oestradiol may regulate telomere length, hence providing a mechanism whereby reproductive steroids are linked to biological ageing in men.
Ada S. Cheung   +5 more
openaire   +3 more sources

Upfront docetaxel with androgen deprivation therapy in the elderly patient with metastatic hormone-naïve prostate cancer: Single institution experience [PDF]

open access: yes, 2018
Upfront docetaxel with androgen deprivation therapy in the elderly patient with metastatic hormone-naïve prostate cancer: Single institution ...
Rea, K   +27 more
core   +1 more source

Menopause hormone therapy in women with cardiovascular risk factors or established ischemic heart disease: A joint FIGO and WHF position paper

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Integrated approach to menopausal hormone therapy in women with cardiovascular risk factors or established ischemic heart disease, from early treatment initiation and risk stratification to individualized therapy, multidisciplinary follow‐up, and health‐system recommendations.
Chiara Benedetto   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy